October 29, 2025 review Open access Complement-targeting therapies in hemolytic diseases Current Opinion in Immunology DOI: 10.1016/j.coi.2025.102686 Full text (OA) OpenAlex Authors 0 Author list not loaded yet. Cited by 0 stored of 2 References 2 Search Sort Most cited Newest Oldest Patent citations Title Any typearticle review book-chapter conference-paper preprint dissertation book dataset other Any fieldAgricultural and Biological Sciences Arts and Humanities Biochemistry, Genetics and Molecular Biology Business, Management and Accounting Chemical Engineering Chemistry Computer Science Decision Sciences Dentistry Earth and Planetary Sciences Economics, Econometrics and Finance Energy Engineering Environmental Science Health Professions Immunology and Microbiology Materials Science Mathematics Medicine Neuroscience Nursing Pharmacology, Toxicology and Pharmaceutics Physics and Astronomy Psychology Social Sciences Veterinary Open access Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria 2021 New England Journal of Medicine article Immunology and Microbiology Complement system in diseases Open access cited by 1 patent 407 citations Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor‐experienced patients with paroxysmal nocturnal hemoglobinuria 2024 American Journal of Hematology article Immunology and Microbiology Complement system in diseases Open access 52 citations 2 results